{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:10:56Z","timestamp":1787163056957,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"vor","delay-in-days":171,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Child Adoles Psych Nursing"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Topic<\/jats:title>\n                    <jats:p>This case report details the treatment of an early adolescent already receiving treatment for attention\u2010deficit hyperactivity disorder who presents with recurrent obsessive\u2010compulsive disorder. Potential atomoxetine (Strattera) and fluoxetine (Prozac) interactions via Cytochrome P450 (CYP450) pathways are examined and alternate therapies are recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Provide a discussion of psychopharmacogenomics, especially in the case of combining medications, CYP450 enzymes, and clinical implications in the context of the burgeoning field of precision medicine. The following questions are addressed: 1) What are the recommendations for pharmacogenetics testing? 2) How should pharmacogenetics inform medication selection? 3) What impact should CYP450 knowledge have on medication dosing?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sources<\/jats:title>\n                    <jats:p>Peer\u2010reviewed journals, U.S. Health and Human Services, National Institutes of Health, National Medical Library, and the Clinical Pharmacology database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genetic testing as a prescriptive tool is not indicated for all medications; however, potential drug\u2013drug interactions, narrow therapeutic drug index, and side effect toxicity contribute to the need for testing. An understanding of CYP450 metabolism and drug interaction as well as metabolism phenotypes should inform prescribing and dosing psychotropic medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jcap.12184","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:15:22Z","timestamp":1516320922000},"page":"126-132","source":"Crossref","is-referenced-by-count":4,"title":["Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-8863","authenticated-orcid":false,"given":"Michaela K.","family":"Hogan","sequence":"first","affiliation":[{"name":"University of Florida  Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-072X","authenticated-orcid":false,"given":"Nikhil P.","family":"Rao","sequence":"additional","affiliation":[{"name":"University of Florida  Gainesville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"2014\u20102015 ADHD Medication Guidelines for Children and Adolescents. (2015).The University of South Florida Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration. Retrieved from:http:\/\/www.medicaidmentalhealth.org\/_assets\/file\/Guidelines\/ADHD%20in%20Children%20and%20Adolescents.pdf"},{"key":"e_1_2_7_3_1","unstructured":"2014\u20102015 Obsessive\u2010Compulsive Disorder Medication Guidelines for Children and Adolescents. (2015).The University of South Florida Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration. Retrieved from:http:\/\/www.medicaidmentalhealth.org\/_assets\/file\/Guidelines\/OCD%20in%20Children%20and%20Adolescents1.pdf."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-2654"},{"key":"e_1_2_7_5_1","unstructured":"Arup Laboratories(2016).Cytochrome P450 Genotype Panel. Available at:https:\/\/outlook.office.com\/owa\/projection.aspx. Accessed: February 13 2017."},{"issue":"11","key":"e_1_2_7_6_1","first-page":"1553","article-title":"Genetic Factors in Drug Metabolism","volume":"77","author":"Belle D. J.","year":"2008","journal-title":"American Family Physician"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-126"},{"issue":"3","key":"e_1_2_7_8_1","first-page":"197","article-title":"Comorbidity and pathophysiology of obsessive\u2013compulsive disorder in schizophrenia: Is there evidence for a schizo\u2010obsessive subtype of schizophrenia","volume":"30","author":"Bottas A.","year":"2005","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.319"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/PGS.15.93"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20160613-01"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","unstructured":"Collins F. S. &Varmus H.(2015).A new initiative on precision medicine.New England Journal of Medicine 372(9) 793\u2013795.","DOI":"10.1056\/NEJMp1500523"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318197748f"},{"key":"e_1_2_7_14_1","volume-title":"Atomoxetine Therapy and CYP2D6 Genotype. Medical Genetics Summaries [Internet]","author":"Dean L.","year":"2015"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1398"},{"key":"e_1_2_7_16_1","volume-title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","author":"Flockhart D. A.","year":"2016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.12.008"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/730956"},{"key":"e_1_2_7_19_1","unstructured":"Gold Standard Inc.An Overview of Fluoxetine. Clinical Pharmacology [database online]. Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: October 16 2016a."},{"key":"e_1_2_7_20_1","unstructured":"Gold Standard Inc.An Overview of Atomoxetine. Clinical Pharmacology [database online]. Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: October 16 2016b."},{"key":"e_1_2_7_21_1","unstructured":"Gold Standard Inc.An Overview of Atomoxetine. Clinical Pharmacology [database online]. Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: January 24 2017a."},{"key":"e_1_2_7_22_1","unstructured":"Gold Standard Inc.An Overview of Citalopram. Clinical Pharmacology [database online]. Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: November 16 2017b."},{"key":"e_1_2_7_23_1","unstructured":"Gold Standard Inc.An Overview of Escitalopram. Clinical Pharmacology [database online].Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: November 16 2017c."},{"key":"e_1_2_7_24_1","unstructured":"Gold Standard Inc.An Overview of Sertraline. Clinical Pharmacology [database online]. Retrieved from:http:\/\/www.clinicalpharmacology.com. Accessed: November 16 2017d."},{"key":"e_1_2_7_25_1","volume-title":"Crossing the quality chasm: a new health system for the 21st century","author":"Institute of Medicine (US). Committee on Quality of Health Care in America","year":"2001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796708.4.1.87"},{"issue":"4","key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.31887\/DCNS.2011.13.4\/ikodish","article-title":"Pharmacotherapy for anxiety disorders in children and adolescents","volume":"13","author":"Kodish I.","year":"2011","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"3","key":"e_1_2_7_28_1","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch T.","year":"2007","journal-title":"American Family Physician"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003533"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(03)00107-1"},{"issue":"6","key":"e_1_2_7_31_1","first-page":"85","article-title":"Prospective, longitudinal study of tic, obsessive\u2010compulsive, and attention\u2010deficit\/hyperactivity disorders in an epidemiological sample","volume":"40","author":"Peterson B. S.","year":"2001","journal-title":"Journal of the American Association of Child and Adolescent Psychiatry"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318054e724"},{"issue":"12","key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1176\/ajp.156.12.1998","article-title":"Obsessive\u2010compulsive disorder in patients with first episode schizophrenia","volume":"156","author":"Poyurovsky S.","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"e_1_2_7_34_1","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Relling M. V.","year":"2011"},{"issue":"4","key":"e_1_2_7_35_1","first-page":"549","article-title":"Herbal and dietary supplements for the treatment of anxiety disorders","volume":"76","author":"Saeed S. Y.","year":"2007","journal-title":"American Family Physician"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.0b013e3182329870"},{"key":"e_1_2_7_37_1","unstructured":"U.S. Health and Human Services National Institutes of Health U.S. National Library of Medicine. (October 11 2016). Cytochrome P450. Retrieved from:https:\/\/ghr.nlm.nih.gov\/primer\/genefamily\/cytochromep450"},{"key":"e_1_2_7_38_1","unstructured":"U.S. Health and Human Services National Institutes of Health. (January 19 2016). Precision medicine initiative cohort program. Retrieved from:https:\/\/www.nih.gov\/precision-medicine-initiative-cohort-program"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn400186j"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530902843483"}],"container-title":["Journal of Child and Adolescent Psychiatric Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcap.12184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcap.12184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:59:30Z","timestamp":1695553170000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcap.12184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/jcap.12184"],"URL":"https:\/\/doi.org\/10.1111\/jcap.12184","archive":["Portico"],"relation":{},"ISSN":["1073-6077","1744-6171"],"issn-type":[{"value":"1073-6077","type":"print"},{"value":"1744-6171","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}